openPR Logo
Press release

Pulmonary Inflammation Market: Emerging niche segments and regional markets

06-21-2017 06:33 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Pulmonary Inflammation Market: Emerging niche segments

Global Pulmonary Inflammation Market: Overview

Pulmonary arteries in our body carries deoxygenated blood from our heart to the lungs. Oxygen is added to the blood into the lungs and it (blood) returned to the heart through pulmonary veins. Pulmonary fibrosis is considered as a chronic disease that can cause swelling and scarring of the alveoli (air sacs) and interstitial tissues in the lungs. The scar tissue formed in the lungs can replace healthy tissue and can cause pulmonary inflammation. Due to pulmonary inflammation our lung becomes stiff that makes breathing very difficult. Etiology for pulmonary inflammation includes emphysema, lung cancer, pulmonary fibrosis, embolism, therapeutic radiation, rheumatoid arthritis and sarcoidosis.

Obtain Report Details: http://www.transparencymarketresearch.com/pulmonary-inflammation-market.html

Breathlessness is identified as the most common symptom of pulmonary inflammation. Dry cough is also considered as very common symptom of pulmonary inflammation. Possible risk factor for suffering from pulmonary inflammation includes cigarette smoking, therapeutic radiation, rheumatoid arthritis and sarcoidosis. Various diagnosis test performed for detection of the pulmonary inflammation includes chest X-ray, pulmonary function test (spirometry), bronchoalveolar lavage test and lung biopsy test. Canadian Lung Association stated that, corticosteroid medication is identified as the most effective treatment for pulmonary inflammation under supervision of a registered medical practitioner. Moreover, it has also stated that, sometimes oxygen therapy is required in order to treat breathlessness.

Global Pulmonary Inflammation Market: Drivers and Restraints

Increasing cigarette smokers and growing prevalence of cancer is considered as a major driving factor of the global pulmonary inflammation treatment market. Moreover, rising prevalence of rheumatoid arthritis cases also accentuates the global market demand of pulmonary inflammation treatment. As an instance, the World Health Organization (WHO) published in 2014, that worldwide 8.2 million people died of cancer in the year 2012. In 2013, American Cancer Society (ACS) published that, around 300,000 men and 276,000 women died due to cancer in 2012 in the U.S. Likewise, emphysema (COPD) is also considered as a major factor that can cause pulmonary inflammation among the global population at a significant rate. Emphysema is mostly caused due to cigarette smoking. According to the Centers for Disease Control and Prevention (CDC), in 2012, North America accounted for the highest number of COPD cases in the world. Moreover, according to the Centers for Disease Control and Prevention (CDC), an estimated 67 million people in the U.S. above 18 years of age would be diagnosed with arthritis by 2030.

Thus, rising prevalence of arthritis and cancer would accentuate the global market demand of pulmonary inflammation treatment. However, technical complexity and high cost associated with diagnosis procedure of pulmonary inflammation might restrict the global market demand of pulmonary inflammation to some extent.

Global Pulmonary Inflammation Market: Regional Analysis

North America and Europe was observed to be the largest pulmonary inflammation market due to major market players are based in these regions. Moreover, technological advancement in diagnostic test and strong demand of diagnostic test would also account for the market growth in these regions. In addition, favorable initiative taken by the federal government also accounted for the pulmonary inflammation treatment market growth in North American and European regions.

Similarly, Asia-Pacific is considered as an untapped market due to lack of proper diagnostic facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Rest of the world (RoW) holds fourth position in the global pulmonary inflammation treatment market due to poor economic and health condition in most of the African countries.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17159

Global Pulmonary Inflammation Market: Companies Mentioned in the Report

Major market players involved manufacturing the therapeutic product of pulmonary inflammation treatment products and contributing the global market share includes Pharmaxis Limited, InDex Pharmaceuticals AB, Resolvyx Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Asmacure Ltee, Celtaxsys, Inc., among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Inflammation Market: Emerging niche segments and regional markets here

News-ID: 588428 • Views: 220

More Releases from TMR - Research Reports

Visualization and 3D Rendering Software Market: On-Premise Deployment Presently …
The global market for visualization and 3D rendering features a largely consolidated vendor landscape, with the leading three vendors accounting for a nearly 80% of the overall revenue generated in the market in 2016, observes Transparency Market Research in a recent report. These three vendors, namely Autodesk Inc., Dassault Systems, and NVIDIA Corporation, have strengthened their positions in the market with the help of cost competitive pricing, continuous introduction of
Digital Door Lock Systems Market: Enhanced Security Requirements to Propel the D …
According to a new market report published by Transparency Market Research titled “Digital Door Lock Systems Market–Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” the global digital door lock systems market was valued at US$ 1,059.5 Mn in 2017 and is expected to expand at a CAGR of 30.25% from 2018 to 2026, reaching US$ 14,877.6 Mn by the end of the forecast period. digital door lock systems market
Transportation Management System Market: Advance Technologies in All the Sectors …
A transportation management system (TMS) refers to a subset of supply chain management and is centered mostly on logistics and transportation. The augmented use of cloud computing technologies for managing supply chain activities is one of the significant and major trends that have been prevailing in the world market for transportation management systems. Cloud-based deployments, in general, need less configuration and customization. These two factors are triggering down the cost
Energy Recovery Ventilators Market: Rising Awareness of Importance of Indoor Air …
Characterized by the presence of a handful of dominant players, namely United Technologies Corp., LG Electronics, Daikin Industries Ltd., Fujitsu Ltd., and Munters Corp., the global energy recovery ventilators market features intense competition, reveals Transparency Market Research (TMR) in a new report. Going forward, the rising number of players seeking entry will further intensify competition in the market. Expansion of product portfolio which has been the focus of established companies to

All 5 Releases


More Releases for Pulmonary

Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Global Pulmonary Arterial Hypertension Market to 2024
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn. PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.
Pulmonary Fibrosis Market Professional Survey Report 2017
Global Pulmonary Fibrosis Market: Snapshot Pulmonary fibrosis belongs to the family of interstitial diseases that can lead to damage of the lungs. As the lung tissue becomes stiff and thickened, it interferes with a person’s ability to breathe. The scarring of lung tissues is associated with a multitude of factors. However, in most cases, the cause of the problem can’t be determined. This state is termed as idiopathic pulmonary fibrosis. While the
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
Latest Report: Global Pulmonary Hypertension Market
MarketResearchReports.Biz presents this most up-to-date research on "Pulmonary Hypertension-Pipeline Insights, 2017" DelveInsights, Pulmonary Hypertension-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Pulmonary Hypertension. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,